Dupilumab - Regeneron/Sanofi

Drug Profile

Dupilumab - Regeneron/Sanofi

Alternative Names: Dupixent; REGN-668; SAR-231893

Latest Information Update: 13 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Regeneron Pharmaceuticals; sanofi-aventis
  • Developer Regeneron Pharmaceuticals; Sanofi
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 13 inhibitors; Interleukin 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Eosinophilic oesophagitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atopic dermatitis
  • Preregistration Asthma
  • Phase III Nasal polyps
  • Phase II Eosinophilic oesophagitis; Grass pollen hypersensitivity
  • Phase I Allergic asthma

Most Recent Events

  • 02 Aug 2018 Regeneron announces intention to submit MAA to the EMA for Atopic dermatitis (In adolescents) in 2018
  • 31 Jul 2018 Sanofi announces intention to submit regulatory submission for Asthma (In children) in 2022
  • 31 Jul 2018 Sanofi announces intention to submit regulatory submission for Eosinophilic oesophagitis in 2022
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top